Literature DB >> 10474721

The pathophysiological and molecular basis of Bartter's and Gitelman's syndromes.

S Bhandari1.   

Abstract

Molecular defects affecting the transport of sodium, potassium and chloride in the nephron through the ROMK K+ channel, Na+/K+/2Cl- cotransporter, the Na+/Cl- cotransporter and chloride channel have been identified in patients with Bartter's and Gitelman's syndromes. Defects of the angiotensin II type I receptor and CFTR have also being described. These defects are simple (i.e., most are single amino acid substitutions) but affect key elements in tubular transport. The simplicity of the genetic defects may explain why the inheritance of these conditions remains unclear in most kindreds (i.e., not just recessive or dominant) and emphasises the crucial importance of the conformational structure of these channels. Application of this molecular information will allow the early genetic identification of patients with these syndromes and enable us to differentiate between the various disorders at a functional level. It may also identify a subgroup in which the heterozygous form may make patients potentially exquisitely sensitive to diuretics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10474721      PMCID: PMC1741279          DOI: 10.1136/pgmj.75.885.391

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  59 in total

1.  Does magnesium play a role in the hypokalemia of Bartter's syndrome?

Authors:  H M Cushner; T P Peller; T Fried; C S Delea
Journal:  Am J Kidney Dis       Date:  1990-11       Impact factor: 8.860

2.  Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome.

Authors:  F C BARTTER; P PRONOVE; J R GILL; R C MACCARDLE
Journal:  Am J Med       Date:  1962-12       Impact factor: 4.965

3.  Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III.

Authors:  D B Simon; R S Bindra; T A Mansfield; C Nelson-Williams; E Mendonca; R Stone; S Schurman; A Nayir; H Alpay; A Bakkaloglu; J Rodriguez-Soriano; J M Morales; S A Sanjad; C M Taylor; D Pilz; A Brem; H Trachtman; W Griswold; G A Richard; E John; R P Lifton
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

4.  Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK.

Authors:  D B Simon; F E Karet; J Rodriguez-Soriano; J H Hamdan; A DiPietro; H Trachtman; S A Sanjad; R P Lifton
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

5.  Cloning of a pH-sensitive K+ channel possessing two transmembrane segments.

Authors:  M Suzuki; K Takahashi; M Ikeda; H Hayakawa; A Ogawa; Y Kawaguchi; O Sakai
Journal:  Nature       Date:  1994-02-17       Impact factor: 49.962

6.  The pathogenetic spectrum of Bartter's syndrome.

Authors:  J H Stein
Journal:  Kidney Int       Date:  1985-07       Impact factor: 10.612

7.  Effects of indomethacin on the vascular abnormalities of Bartter's syndrome.

Authors:  C J Richards; A L Mark; D E Van Orden; G J Kaloyanides
Journal:  Circulation       Date:  1978-09       Impact factor: 29.690

8.  Bartter's syndrome and diabetes mellitus.

Authors:  G Venkat Raman; J D Albano; J G Millar; H A Lee
Journal:  J Intern Med       Date:  1990-11       Impact factor: 8.989

Review 9.  [Renin gene analysis of familial Bartter's syndrome].

Authors:  J Higaki; T Ogihara
Journal:  Nihon Rinsho       Date:  1992-12

10.  Electrolyte disturbances and cardiac failure with hypomagnesaemia in anorexia nervosa.

Authors:  V Fonseca; C W Havard
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-14
View more
  2 in total

Review 1.  Molecular physiology of urinary concentration defect in elderly population.

Authors:  B K Kishore; C M Kran; M Reif; A G Menon
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  Congenital long QT syndrome aggravated by salt-wasting nephropathy.

Authors:  Dawood Darbar; Saba Sile; Frank A Fish; Alfred L George
Journal:  Heart Rhythm       Date:  2005-03       Impact factor: 6.343

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.